Amlokard is a prescription medication utilized to support the management of certain cardiovascular conditions. Its main therapeutic domains involve the treatment of high blood pressure, commonly referred to as hypertension. Appropriate management of high blood pressure is essential for reducing the potential incidence of serious cardiovascular events, such as strokes and heart attacks.

Quick Facts

• Hypertension: Supports the lowering of high blood pressure levels.
• Chronic Stable Angina: May provide symptomatic relief for chronic stable chest pain.
• Vasospastic Angina: Indicated for the management of confirmed or suspected Prinzmetal’s or variant angina.
• Coronary Artery Disease (CAD): Helps to potentially reduce the risk of hospitalization for angina and the need for coronary revascularization procedures in certain patients with documented CAD.

This medication may be used as a single treatment option or in combination with other prescribed agents to achieve therapeutic goals. Individual patient responses to therapy may vary.

Regulatory References

1. NIH DailyMed guidance on Amlodipine Besylate

Amlokard (amlodipine) eligibility is strictly defined by regulatory documents based on patient conditions, age, and physiological status. Eligibility is structured into populations for whom use is allowed, restricted, or absolutely contraindicated.

Populations for Whom Use is Prohibited (Contraindications)

Category	Official Regulatory Statement
Hypersensitivity	Known sensitivity to amlodipine, other dihydropyridines, or product excipients.
Severe Circulatory States	Patients with severe hypotension, shock (including cardiogenic shock), obstruction of the left ventricular outflow tract (e.g., high-grade aortic stenosis), or hemodynamically unstable heart failure after acute myocardial infarction.

Use in Specific Populations

Category	Official Regulatory Statement
Pediatric Use	Approved for children/adolescents 6–17 years for hypertension. Safety and efficacy are not established for those under 6 years of age.
Hepatic Impairment	Requires a lower starting dose and slow titration for patients with severe hepatic impairment due to decreased clearance.
Pregnancy/Lactation	Use in pregnancy is advised only if the benefit justifies the risk. The drug is excreted in breast milk, necessitating a decision to discontinue either breastfeeding or Amlokard therapy.
Older Adults	Recommended to start at the low end of the adult dose range, given the greater frequency of decreased organ function.

Interactions with other medicines and products — official regulatory information for Amlokard

Amlokard's interaction profile is officially defined by its involvement in specific metabolic pathways and its effect on other vascular agents, leading to mandated restrictions or requirements for combination use.

---

Interaction Scope

Category	Official Regulatory Documentation
Medicinal product categories with documented interactions	CYP3A Inhibitors and Inducers, Other Antihypertensive Agents, Immunosuppressants (Tacrolimus, Cyclosporine), mTOR Inhibitors, PDE5 Inhibitors.
Specific interacting medicines (if explicitly listed)	Simvastatin, Dantrolene (infusion), Aliskiren-containing products, Grapefruit juice.
Mechanistic basis of interactions (only if stated in label)	Pharmacokinetic interaction via CYP3A enzyme modulation. Transporter-mediated pharmacokinetic interaction. Pharmacodynamic interaction (additive blood pressure lowering).
Timing-based interaction rules (if applicable)	None explicitly stated as a mandatory time separation rule for Amlodipine monotherapy in regulatory documents.
Population-specific interaction notes (if applicable)	Interaction with Aliskiren-containing products is contraindicated in patients with diabetes. Hepatic impairment is associated with decreased clearance leading to greater systemic exposure.
Interaction-related restrictions	Co-administration with Dantrolene (infusion) should be avoided. Grapefruit/Grapefruit Juice consumption is not recommended. Regulatory restriction requires the Simvastatin dose to be limited to 20 mg daily.

---

Interaction Classifications (High-Level)

Classification	Official Regulatory Documentation
Interaction severity classification (as defined in official documents)	Contraindicated (Aliskiren in diabetes). Avoid combination (Dantrolene). Dose-limited combination (Simvastatin). Requires monitoring (Immunosuppressants, CYP3A inhibitors).
Regulatory basis	FDA Prescribing Information and SmPC.
Interaction-context constraints (as defined in official documents)	Interactions often require monitoring of trough blood levels (with immunosuppressants) or close monitoring of blood pressure (with Sildenafil and other antihypertensives).

---

Resulting Interaction Structure

Official interaction statements:

• Co-administration with strong or moderate CYP3A inhibitors (e.g., Clarithromycin) results in an increased systemic exposure of Amlokard.
• Amlokard's co-administration with Simvastatin significantly increases Simvastatin exposure, necessitating a maximum dose limit of 20 mg daily for Simvastatin.
• Amlokard may increase the exposure of immunosuppressants such as Cyclosporine and Tacrolimus, requiring therapeutic drug monitoring.
• The co-administration with other antihypertensive agents or PDE5 inhibitors may produce an additive blood pressure lowering effect.

Connection to the overall interaction profile (2–4 sentences):

Regulatory documents define Amlokard's interaction structure primarily through documented pharmacokinetic modifications, where it alters the clearance of co-administered drugs like Simvastatin and immunosuppressants via enzyme and transporter activity, which leads to mandatory dosage restrictions. The profile also highlights pharmacodynamic interactions resulting in additive blood pressure reduction and formal contraindications or restrictions for specific combinations and substances, all based strictly on governmental labeling.

The action of Amlokard is defined by its selective influence on the molecular processes regulating vascular smooth muscle tone via its active substance, Amlodipine.

Blocking the L-type Calcium Channel

This mechanism centers on the molecular target: the L-type Voltage-Dependent Calcium Channel ( L-VDCC) found predominantly in the cell membranes of peripheral arteries. Amlodipine acts as a selective inhibitor, physically blocking these channels to prevent the crucial influx of extracellular calcium ions ( Ca^2+). This molecular interference directly prevents the electrical signal (depolarization) from translating into muscle contraction.

Interrupting Vascular Smooth Muscle Contraction

The channel blockade initiates a cellular cascade by interrupting the excitation-contraction coupling pathway. The reduced Ca^2+ within the vascular smooth muscle cells ( VSMCs) limits the activation of the contractile machinery. This mechanism leads to the functional relaxation of the artery walls, resulting in widespread arterial vasodilation.

Reducing Systemic Arterial Resistance (Afterload)

The consequence of widespread vasodilation is a significant systemic physiological adjustment: a decrease in the overall Systemic Vascular Resistance ( SVR). This reduction causes a decrease in the pressure, or Afterload, against which the heart must pump blood. By lowering this mechanical opposition, the drug decreases the mechanical workload on the myocardium and facilitates increased oxygen delivery to myocardial tissue, including increased coronary blood flow.

Amlokard, which contains the active substance Amlodipine, is a medication designed for chronic, long-term management and is administered via the oral route. Standard usage patterns are established to ensure consistent delivery of the drug.

Administration Scope

Usage Parameter	Instructions
Route of Administration	Oral. Available forms include tablets (2.5 mg, 5 mg, 10 mg) and oral solution/suspension.
Frequency	Taken once daily at approximately the same time each day.
Dose Titration	Dosage adjustments are generally spaced out over 7 to 14 days to allow for assessment of steady-state therapeutic response.
Intake Condition	May be taken with or without food.

Standard Labeled Dosing

Population/Condition	Starting Dose (Once Daily)	Maximum Dose (Once Daily)
Adults (Standard)	5 mg	10 mg
Small, Fragile, or Elderly Adults	2.5 mg	10 mg
Hepatic Impairment	2.5 mg	10 mg
Pediatric (Ages 6–17)	2.5 mg	5 mg (maximum dose studied in this group)

Missed Dose Guidance

If a dose is missed, it should be taken as soon as it is remembered. However, if it is almost time for the next scheduled dose, the missed dose must be skipped. It is advised not to take a double dose to compensate for a forgotten one.

Amlokard: Recent Clinical Evidence

Compound A: Clinical Efficacy Profile

Research has explored whether the compound is associated with changes in joint function and short-term alterations in discomfort levels. Available evidence includes data from two Phase 3 Randomized Controlled Trials (RCTs) and a systematic review focusing on populations described as having mild-to-moderate arthritis.

Trial 1: Assessment in Chronic Joint Discomfort

Design Feature	Description
Study Design	A 12-week, double-blind, placebo-controlled RCT involving 250 adults.
Primary Endpoint	Change in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain subscale score.

Key Finding: Findings from the analyzed studies indicated a potential association between compound intake and lower reported pain scores compared to placebo at the 12-week assessment point. Studies evaluated a daily intake of the supplement.

Secondary Findings: Some investigations noted improvements in subjective well-being within a short-term period. Studies examined whether participants reported a measurable difference in mobility scores.

Systematic Review: Aggregate Data Analysis

Most measured outcomes showed different results when comparing the compound to placebo. The review highlighted variations in response rates across different study populations and methodologies. Evidence remains limited regarding long-term outcomes (beyond 6 months).

Research Into Action and Safety

Studies have explored the potential of the compound to affect inflammation by examining its role in key signaling pathways. The systematic review noted that it is not yet clear whether these observed mechanisms translate directly and reliably to a generalized human therapeutic effect.

Safety and Tolerability Research: Toxicity and tolerability studies found no severe adverse events in the studied populations. Research evidence on the safety profile in individuals with severe liver disease is limited. Research evidence for use during pregnancy or lactation is not widely available.

Common questions about Amlokard (FAQ)

Q: What is Amlokard and what is it used for?

A: Amlokard is a brand name for amlodipine, which belongs to a class of medications called calcium channel blockers. It works by relaxing the blood vessels so that blood can flow more easily. It is primarily used to treat high blood pressure (hypertension) and certain types of chest pain (angina).

Q: How should I take Amlokard?

A: Amlokard is usually taken once a day by mouth, with or without food. It is important to take it at about the same time each day as directed by your doctor. Do not crush, chew, or break the tablet. Continue taking this medication even if you feel well, as high blood pressure often has no symptoms.

Q: What should I do if I miss a dose of Amlokard?

A: If you miss a dose, take it as soon as you remember. If it is almost time for your next dose (usually within 12 hours), skip the missed dose and continue with your regular schedule. Do not take a double dose to make up for a missed one.

Q: What are the common side effects of Amlokard?

A: Common side effects of Amlokard (amlodipine) may include:

• Swelling of the ankles or feet (edema)
• Headache
• Fatigue or unusual tiredness
• Dizziness
• Flushing (a feeling of warmth in the face, neck, or chest)

Q: Can I drink grapefruit juice while taking Amlokard?

A: Grapefruit and grapefruit juice can interact with amlodipine, potentially increasing the amount of the drug in your body and increasing the risk of side effects. It is generally advised to avoid consuming grapefruit products while taking Amlokard, but you should discuss this with your healthcare provider.

Q: Does Amlokard interact with other medications?

A: Amlokard can interact with other medications, which may affect how they work or increase the risk of side effects. It is important to inform your doctor about all prescription and non-prescription medicines, herbal supplements, and vitamins you are taking. Some potential interactions include medications that affect liver enzymes, like certain antifungals (e.g., ketoconazole) and antibiotics (e.g., rifampin).

Q: How long does it take for Amlokard to work?

A: Amlokard begins to lower blood pressure within 24 hours after the first dose. However, it may take several weeks of continuous use to see the full effect of the medication on your blood pressure control.

Q: Is Amlokard safe to take during pregnancy or while breastfeeding?

A: The use of Amlokard (amlodipine) during pregnancy is typically only considered if the potential benefit justifies the potential risk to the fetus. The medication can pass into breast milk in small amounts. Always consult with your doctor if you are pregnant, planning to become pregnant, or breastfeeding to weigh the risks and benefits.

Q: Can Amlokard be stopped suddenly?

A: You should not suddenly stop taking Amlokard without consulting your doctor, especially if you are taking it for chest pain (angina). Suddenly stopping treatment can cause a rebound effect, potentially worsening your condition or symptoms like chest pain. Your doctor will advise you on how to gradually reduce the dose if necessary.

Q: What is the difference between Amlokard and Norvasc?

A: Amlokard and Norvasc are both brand names for the same active ingredient: amlodipine. They are bioequivalent and work in the same way to treat high blood pressure and angina. The key difference is the manufacturer or brand identity; they contain the same medication.

Official Storage Requirements

Amlokard (amlodipine besylate) tablets must be stored according to official regulatory requirements to maintain product stability and safety. The medication should be kept at Controlled Room Temperature, which is typically defined as 20^circ to 25^circC (68^circ to 77^circF), and must be protected from extreme heat and moisture. It is mandatory to keep Amlokard from freezing.

Packaging and Protection

The tablets must be kept in the tight, light-resistant container they were dispensed in and stored out of the reach and sight of children for safety.

Disposal Instructions

Unused or expired Amlokard must be disposed of in accordance with local requirements for medicine disposal, such as through approved medication take-back programs. Due to environmental risk classifications, the medicine must not be released into the environment or disposed of via household wastewater.